Stanford University
Showing 51-60 of 122 Results
-
Yong Yean Kim
Assistant Professor of Pediatrics ( Hematology & Oncology)
BioOur lab is interested in translational science to bring new therapies to clinical trials. In particular, we are interested in pediatric sarcomas which have not had advancement in clinical treatment for decades. Current projects in the lab focus on understanding of the biology of fusion transcription factor PAX3::FOXO1 which is the driver mutation in fusion positive rhabdomyosarcoma. PAX3::FOXO1 is a powerful oncogenic transcription factor which rewires the transcriptional organization to lock the cancer cell in the proliferative state. Since transcription factors including PAX3::FOXO1 are difficult to target using small molecules, we aim to understand how PAX3::FOXO1 is regulated and targeting the regulators of PAX3::FOXO1. By understanding and targeting the regulation of PAX3::FOXO1, we hope to bring new therapies for fusion positive rhabdomyosarcoma. Additionally, these regulatory mechanisms may also be active in other transcription driven cancers such as the EWSR1::FLI1 driven Ewings Sarcoma.
Our lab is also interested in exploring the epigenetic landscape of pediatric solid tumors and trying to understand how dysregulation in the epigenome drives oncogenesis. We utilize various CRISPR mediated genetic techniques to interrogate the regulators of epigenome focusing on the histone lysine demethylases (KDMs). KDMs are an understudied group of epigenetic regulators which can be targeted for therapeutic effect. We explore the role of KDMs in pediatric solid tumors and hope to identify potential targets for drug development. -
Norman J. Lacayo, MD
Associate Professor of Pediatrics (Hematology and Oncology)
Current Research and Scholarly InterestsPediatric Hematology/Oncology, Phase I drug studies for refractory and relapsed leukemia; genomic studies, biologic risk-stratification and treatment of acute myeloid leukemia; prediction or induction response and risk of relapse using phosphoproteomics in childhood AML; novel MRD techniques in childhood ALL.
-
Michael Link
Lydia J. Lee Professor of Pediatric Cancer
Current Research and Scholarly InterestsHematology/Oncology, treatment of sarcomas of bone and soft tissue, biology of acute lymphoblastic leukemias, treatment of non-Hodgkin's lymphoma and Hodgkin's disease.
-
Y. Lucy Liu, MD, PhD
Affiliate, Pediatrics - Hematology/Oncology
BioDr. Liu received her medical and clinical pharmacology training at two of the most prestigious medical institutions in China—West China School of Medicine (Sichuan University) and Peking Union Medical College (PUMC). She possesses extensive research experience in human molecular genetics, tumor biology, and experimental therapeutics.
Dr. Liu is internationally recognized for her expertise in two rare pediatric hematologic disorders: juvenile myelomonocytic leukemia (JMML) and Diamond-Blackfan anemia (DBA). She has authored more than 30 peer-reviewed publications in leading scientific journals, including Nature Genetics, Blood, Leukemia, and the Journal of Clinical Investigation (JCI). At her previous institutions, Dr. Liu served as a Principle Investigator (PI) and co-investigator on several NIH-funded research projects. In 2019, Dr. Liu joined the Department of Pediatrics at the Stanford University School of Medicine as a Senior Research Scientist. She recently developed a novel mouse model for DBA, which has proven to be a valuable tool for evaluating potential therapeutic strategies. Her current research focuses on elucidating the molecular pathogenesis of DBA and developing innovative treatment approaches for DBA. Since joining Stanford, Dr. Liu has published multiple manuscripts highlighting her ongoing research contributions.
